

Optimizing health outcomes in heart failure and multimorbidity: A multidisciplinary expert, consensus, scientific statement (Abridged Version)

A. Authors

The authors comprise a multidisciplinary team of health care professionals (including Cardiologists, Geriatricians, Internal Medicine Specialists, Nurses and Human Movement Specialists) with an active interest and expertise relevant to multimorbidity and heart failure (HF) - Simon Stewart, Barbara Riegel, Cynthia Boyd, Yasmin Ahamed, David R Thompson, Louise Burrell, Melinda J Carrington, Andrew JS Coats, Bradi Granger, Julie Hides, William Weintraub, Debra K Moser, Victoria Vaughan & Michael Rich.

B. Brief Background

As described in the main application documents, multimorbidity in HF, defined by the *presence of HF of any etiology and two or more concurrent conditions that require active management*, represents a growing problem within the ageing HF patient population. Expert guidelines struggle to articulate how this multifactorial problem can be effectively addressed – hence this initiative.

C. Expert Consensus Aims

In recognizing the complex clinical challenges inherent to managing HF in the setting of multimorbidity and the role of expert guidelines in providing a comprehensive overview of the relative strengths and applicability of treatment options, the specific aims of this *Expert Consensus Statement* were two-fold:

1. To provide a comprehensive overview of the current literature focusing on the most common conditions requiring concurrent treatment and management in patients with HF.
2. To derive a practical set of recommendations for a systematic response to this increasingly common clinical phenomenon.

As such, we expect our pragmatic recommendations (from an international, multidisciplinary panel of health professionals with an ongoing interest and expertise in HF management) to complement contemporary guidelines to generate new initiatives to improve health outcomes in all affected individuals; regardless of the health care system in which they are managed.

D. Methods

We sought to derive a set of key recommendations (on a consensus basis) to guide future health policy and clinical practice in this area. Our recommendations are based on the following: **1)** an initial review of the literature identifying the ten most common conditions, other than hypertension and ischaemic heart disease, complicating the management of HF (anemia, arrhythmias, cognitive dysfunction, depression, diabetes, musculoskeletal disorders, renal dysfunction, respiratory disease, sleep disorders and thyroid disease), **2)** a systematic review of the published literature (2005 – 2015) describing HF and these ten conditions (195 published papers) and **3)** our expertise and experiences in managing complex patients with HF and multimorbidity.

E. Findings & Recommendations

Overall the published literature shows an increasing interest (both in volume and sophistication), but inherently fragmented approach to characterizing multimorbidity in HF. After carefully considering the available literature relative to our collective clinical experiences and practice and consistent with previous calls for a more systematic response to this growing clinical problem we made five key recommendations:

1. Multimorbidity in HF be recognized as a distinct clinical entity

As previously noted by Tinetti and colleagues (1), multimorbidity in HF has emerged as a distinct clinical entity associated with poor health outcomes and should be recognized as such to provoke a more systematic response. It is of particular concern that HF patients with a high burden of multimorbidity living in low-income areas are at increased risk of all-cause re-hospitalization: suggesting that illness burden influences the association between income and outcomes in these patients (2).

2. All patients hospitalized with HF should be routinely screened for multimorbidity

A logical extension to recognizing multimorbidity in HF as a distinct clinical entity is to identify which patients are affected. As such, we recommend all patients admitted to hospital with HF should be systematically screened for multimorbidity (full screening at least every 12 months if multiple admissions) in order to quantify the extent and nature of the problem. This should be noted in the clinical records as part of any communication to patient's wider health care team. It is important to note that any screening protocol will likely rely on a component of "routine" profiling, but also require an active component of profiling beyond current clinical practice (e.g. to determine cognitive function). **Table 1** summarizes the definitions and methods that could be routinely applied (with local adaptations) to identify the 10 most common comorbid conditions in HF.

Table 1: Routine Screening for multimorbidity in Heart Failure

Co-morbidity	Data source and determination	Definition / deficit threshold
Anemia	Full blood examination during hospital admission	Serum Hb level <130 (women) / <120 g/l (men) (3)
Atrial and ventricular arrhythmias	Review of medical notes with plus review of prescribed pharmacotherapy at discharge If high clinical suspicion of undiagnosed arrhythmia - 12-lead ECG, inpatient telemetry or extended ECG Holter monitoring	Confirmation of AF, other atrial arrhythmias, 2 nd or 3 ^r degree heart block, VT/VF with prescription of anti-arrhythmic therapy or pacemaker/ defibrillator device (4)
Cognitive impairment/dementia	Assessed via Montreal Cognitive Assessment (MoCA) tool prior to hospital discharge by trained personnel	MoCA score < 26 out of a maximal possible score of 30. (5)
Depression/Anxiety	Assessed via PQ-2 (6) questionnaire prior to hospital discharge by trained personnel plus review of medical notes and prescribed pharmacotherapy at discharge. If positive, apply more comprehensive tool (e.g. HADS) (7)	Positive response to depressive symptoms and/or confirmed diagnosis (with active anti-depressive/anxiolytic) of depression or anxiety
Diabetes and metabolic disorders	Review of medical notes and prescribed pharmacotherapy at discharge Calculation of body mass index If high clinical suspicion of underlying diabetes HbA1c and/or glucose tolerance tests	Documented diagnosis of Type 2 Diabetes or obesity BMI > 30kg/m ² plus dyslipidemia and/or hypertension (metabolic syndrome)
Musculoskeletal disorders	Review of medical notes and prescribed pharmacotherapy at discharge Frailty test with hand-grip manometer (8)	Documented diagnosis of arthritis, osteoporosis, gout or any other musculoskeletal condition requiring active therapy (e.g. anti-inflammatory or analgesia) This could be achieved by obtaining blood tests in addition to whole body scans via dual X-ray absorptiometry (DXA)
Renal impairment	Electrolytes and renal function obtained during hospital admission Calculation of body mass index	Estimated glomerular filtration rate < 60 mL/min/1.73m ² (9)
Respiratory disease	Review of medical notes and prescribed pharmacotherapy at discharge If high clinical suspicion of underlying respiratory disease – formal lung function tests	Lung function confirmation of COPD, asthma and/or other chronic pulmonary condition requiring active treatment (10)
Thyroid disease	Review of medical notes and prescribed pharmacotherapy at discharge If high clinical suspicion of, or historical lack of screening, perform thyroid function tests (including thyroid stimulating hormone levels) at hospital admission	Documented hyper/hypothyroidism based on according to national standards with associated anti-thyroid or thyroxine replacement therapy (11)
Sleep disorders	Review of medical notes and prescribed sleep support device. If high clinical suspicion of sleep disordered breathing perform formal sleep studies Use of a screening questionnaire in hospital to identify those with sleep-disordered breathing (12)	Documented diagnosis of obstructive or central sleep disordered breathing

3. Based on the extent/complexity of multimorbidity a list of individualized clinical priorities and goals be established

There are potentially many competing priorities arising from multimorbidity in HF that are not easily addressed in a generic manner – hence the historical difficulty for expert guideline committees to provide specific recommendations in the setting of marginal benefit-risk ratios. For example, there has been a traditional reluctance to apply high doses of neurohormonal/vasodilator therapy in the setting of frailty and high risk of falls and/or evidence of progressive renal dysfunction; despite the potential benefits overall (13, 14). It is on this basis that we recommend that in considering the nature and level of multimorbidity a formal list of clinical priorities should be considered by the treating physician and wider multidisciplinary team with

consideration of the need for specialist opinion for particularly difficult conditions, patient preferences and goals (15) and conflicting/contraindicated treatment options based on the same (see **Table 2**).

4. Individualized, home-based, multidisciplinary, case management be strongly considered to supplement standard HF management

As recently articulated in the AHA/ACC/HHS Strategies to Enhance Application of Clinical Practice Guidelines in Patients with Cardiovascular Disease and Comorbid Conditions (16), there is increasing imperative to adjust management strategies towards multimorbidity and standard HF management are no exception. Beyond recognizing and counting any particular problem (see recommendations 1-3), strategic plans that are robust (in most health care systems), flexible, workable and cost-effective to address that problem need to be formulated. Beyond summarizing the literature, this forms the major component on this Expert Consensus Statement. Unfortunately, despite the frequency of multimorbidity in HF, interventions applicable to these patients are scarce and to our knowledge there is no definitive approach to improve typically poor health outcomes over above standard HF management models of care. The inherent complexity of managing multiple comorbid conditions is exacerbated by issues such as frailty, social isolation, impaired cognition and limited income that frequently accompanies sufferers of HF, who are typically elderly (17-19) Interventions addressing multimorbidity and clinical complexity in this population have the potential to reduce hospitalizations and prolong survival beyond that achieved by traditional disease management programs or transitional care; particularly targeting residually poor communication and poorly coordinated transitions during hospital discharge between health care providers that contributes to negative health outcomes and increased financial burden on the healthcare system. However, new research to fully harness the potential of outreach models of care with case-management and empowering patients and their carers to prioritise and address potentially conflicting clinical and personal goals is urgently required.

5. Evaluation of outcomes in HF and multimorbidity should extend well beyond the short-term and encompass all-cause events and person-centered perspective

Despite an understandable focus on immediate and costly rebounds to hospital in the short-term (i.e. within 30-days) (20-23), there is a strong rationale for adopting a longer and more holistic perspective to reflect the entire patient journey for those with HF and multimorbidity. The classical description and understanding of the natural history of HF reinforces this point; noting how periods of clinical instability in those affected by HF typically correlate with recurrent periods of hospital stay (24). However, a good proportion of individuals with HF may spend a reasonably extended period of time in a relatively stable phase once their most immediate clinical issues are resolved.

F. Summary Conclusions

Multimorbidity and HF represents a growing health threat from the societal to individual perspective. Current health care strategies need to be adapted (as per our five key recommendations) to improve typically poor health outcomes in this clinical setting. Figure 1 shows how are recommendations might be easily applied in the clinical setting.




Figure 1: Putting the five key recommendations into practice

Abbreviated References

1. Tinetti ME, Fried TR, Boyd CM. Designing health care for the most common chronic condition--multimorbidity. *JAMA : the journal of the American Medical Association*. 2012;307(23):2493-4.
2. Foraker RE, Rose KM, Suchindran CM, Chang PP, McNeill AM, Rosamond WD. Socioeconomic status, Medicaid coverage, clinical comorbidity, and rehospitalization or death after an incident heart failure hospitalization: Atherosclerosis Risk in Communities cohort (1987 to 2004). *Circulation Heart failure*. 2011;4(3):308-16.
3. Pasricha SR, Flecknoe-Brown SC, Allen KJ, Gibson PR, McMahon LP, Olynyk JK, et al. Diagnosis and management of iron deficiency anaemia: a clinical update. *The Medical journal of Australia*. 2010;193(9):525-32.
4. Gregoratos G, Cheitlin MD, Conill A, Epstein AE, Fellows C, Ferguson TB, Jr., et al. ACC/AHA guidelines for implantation of cardiac pacemakers and antiarrhythmia devices: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Pacemaker Implantation). *J Am Coll Cardiol*. 1998;31(5):1175-209.
5. Doerflinger DMC. Mental Status Assessment in Older Adults: Montreal Cognitive Assessment: MoCA Version 7.1 (Original Version). Virginia.
6. Lowe B, Wahl I, Rose M, Spitzer C, Glaesmer H, Wingenfeld K, et al. A 4-item measure of depression and anxiety: validation and standardization of the Patient Health Questionnaire-4 (PHQ-4) in the general population. *J Affect Disord*. 2010;122(1-2):86-95.
7. Rutledge T, Reis VA, Linke SE, Greenberg BH, Mills PJ. Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. *J Am Coll Cardiol*. 2006;48(8):1527-37.
8. Gary R. Evaluation of frailty in older adults with cardiovascular disease: incorporating physical performance measures. *The Journal of cardiovascular nursing*. 2012;27(2):120-31.
9. Zamora E, Lupon J, Vila J, Urrutia A, de Antonio M, Sanz H, et al. Estimated glomerular filtration rate and prognosis in heart failure: value of the Modification of Diet in Renal Disease Study-4, chronic kidney disease epidemiology collaboration, and cockcroft-gault formulas. *J Am Coll Cardiol*. 2012;59(19):1709-15.
10. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. *Eur Respir J*. 2004;23(6):932-46.
11. Gerdes AM, Iervasi G. Thyroid replacement therapy and heart failure. *Circulation*. 2010;122(4):385-93.
12. Sharma S, Mather P, Eford JT, Kahn D, Cheema M, Rubin S, et al. Photoplethysmographic Signal to Screen Sleep-Disordered Breathing in Hospitalized Heart Failure Patients Feasibility of a Prospective Clinical Pathway. *JACC: Heart Failure*. 2015;3(9):725-31.
13. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. *European heart journal*. 2012;33(14):1787-847.
14. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Jr., Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. *Circulation*. 2013;128(16):1810-52.
15. Whitty JA, Stewart S, Carrington MJ, Calderone A, Marwick T, Horowitz JD, et al. Patient preferences and willingness-to-pay for a home or clinic based program of chronic heart failure management: findings from the Which? trial. *PLoS One*. 2013;8(3):e58347.
16. Arnett DK, Goodman RA, Halperin JL, Anderson JL, Parekh AK, Zoghbi WA. AHA/ACC/HHS strategies to enhance application of clinical practice guidelines in patients with cardiovascular disease and comorbid conditions: from the American Heart Association, American College of Cardiology, and US Department of Health and Human Services. *Circulation*. 2014;130(18):1662-7.
17. Freedland KE, Carney RM. Psychosocial considerations in elderly patients with heart failure. *Clinics in geriatric medicine*. 2000;16(3):649-61.
18. Kerzner R, Rich MW. Management of heart failure in the elderly. *Current cardiology reports*. 2003;5(3):223-8.

19. Norberg EB, Boman K, Lofgren B, Brannstrom M. Occupational performance and strategies for managing daily life among the elderly with heart failure. *Scandinavian journal of occupational therapy*. 2014;21(5):392-9.
20. Allen LA, Smoyer Tomic KE, Smith DM, Wilson KL, Agodoa I. Rates and predictors of 30-day readmission among commercially insured and Medicaid-enrolled patients hospitalized with systolic heart failure. *Circulation Heart failure*. 2012;5(6):672-9.
21. Bradley EH, Curry L, Horwitz LI, Sipsma H, Wang Y, Walsh MN, et al. Hospital strategies associated with 30-day readmission rates for patients with heart failure. *Circulation Cardiovascular quality and outcomes*. 2013;6(4):444-50.
22. Hernandez MB, Schwartz RS, Asher CR, Navas EV, Totfalusi V, Buitrago I, et al. Predictors of 30-day readmission in patients hospitalized with decompensated heart failure. *Clinical cardiology*. 2013;36(9):542-7.
23. Wexler R. Early physician follow-up and 30-day readmission among older patients with heart failure. *JAMA : the journal of the American Medical Association*. 2010;304(7):743; author reply -4.
24. Goodlin SJ. Palliative care in congestive heart failure. *J Am Coll Cardiol*. 2009;54(5):386-96.

Supplementary Table 1: Summary of the literature most relevant to the concurrent management of heart failure (HF) and the ten pre-specified concurrent conditions

Co-morbidity	Prevalence & Impact on heart failure (HF)	Management Options	Clinical Caveats & Considerations
<p>Anaemia and reduced haemoglobin (Hb) levels</p>	<ul style="list-style-type: none"> • Commonly reported in HF, anaemia occurs in 20-30% of patients with the syndrome (1-3) • Anaemia is associated with an increased risk of hospitalisation (3) • New onset anaemia is common in chronic heart failure (CHF) patients. Over time this relates to increased morbidity and mortality (1) • There are no generally accepted guidelines regarding the treatment of anaemia in CHF (3) • Low Hb levels are associated with HF-related fatigue (comparable to cancer-related fatigue) (4, 5) • Correlated with increases in morbidity and mortality (1, 6, 7) • It is unclear whether anaemia is a cause or a consequence of the low-output HF and its aetiology is multifactorial (8, 9) • Risk factor for development of HF (10) • Iron deficiency is a valid independent therapeutic target (11). It is common in CHF in both those who are anaemic and non-anaemic. • Iron deficiency is more commonly found in non-anaemic women with CHF than non-anaemic men with CHF (12, 13) 	<ul style="list-style-type: none"> • Increase Hb levels via erythropoietin (14) • Clinical practice guidelines (American College of Physicians) suggest using erythropoiesis-stimulating agents to increase Hb levels in patients with mild to moderate anaemia with acute heart failure or coronary heart disease (15). However, this form of treatment is not recommended for routine use in those with CHF (16) • Intravenous ferric carboxymaltose improves symptoms, functional capacity, and quality of life (QoL) in stable, symptomatic, ambulatory patients with the syndrome (11) • Intravenous (IV) iron is superior to oral iron in improving functional capacity of CHF patients. Both IV and oral iron is effective in correcting anaemia (IRON-HF RCT) (6) • Iron replacement therapy (oral or IV) improves QoL, exercise capacity as tested via the 6-metre walk test (6MWT) (17), and reduces hospitalisations overall (3) • Iron status needs to be routinely monitored in patients with the syndrome and in particular those who are re-hospitalised for worsening HF (12, 18). Thus, routine monitoring of iron levels in this population is advised (19) 	<ul style="list-style-type: none"> • Increasing Hb levels via erythropoietin treatment has been associated with an excess of vascular events • Oral and intravenous ferric carboxymaltose therapy is safe, well-tolerated and has no adverse side effects (11) but more trials assessing this are required (3, 11) • There is mixed evidence on the use of Darbepoetin Alfa for treatment of anaemia in those with HF with reduced ejection fraction (HFrEF) (i.e. systolic dysfunction) and moderate anaemia. Some studies report it does not improve clinical outcomes in this clinical setting (13, 14, 20) and others report improvement in Hb levels with no adverse side effects (21-23) • Red blood cell (RBC) transfusion in patients with acute coronary syndrome (ACS) significantly increases risk of mortality and is not recommended as a safe form of treatment (24)
<p>Atrial and ventricular</p>	<ul style="list-style-type: none"> • Atrial fibrillation (AF) and HF share common 	<ul style="list-style-type: none"> • Beta-blockers and/or digoxin are the drugs 	<ul style="list-style-type: none"> • Some studies have failed to

Co-morbidity	Prevalence & Impact on heart failure (HF)	Management Options	Clinical Caveats & Considerations
arrhythmias	<p>risk factors, often coexist (up to 50% depending on the patient's age and clinical profile), and confer additive adverse effects when occurring simultaneously (25, 26)</p> <ul style="list-style-type: none"> • Patients with AF exhibit increased risk of mortality due to HF and stroke (25) • Ventricular arrhythmias (VA's) are frequent in HF patients, particularly in those with a dilated left ventricular and reduced left ventricular ejection fraction (LVEF) (27) 	<p>of choice for rate control in patients with concomitant HF and AF because of their known benefits in HF (27, 28)</p> <ul style="list-style-type: none"> • Anti-arrhythmic drugs are the first-line rhythm control option for AF (refer to clinical caveats & considerations) (29) • In patients who fail pharmacologic rate control, atrioventricular node ablation and ventricular pacing can be attempted (30) • For rhythm control, immediate electrical cardioversion is recommended for HF patients with new-onset AF when pharmacological measures have failed (27) 	<p>demonstrate a benefit of beta-blockade in HF patients who also have AF (31, 32) (A treatment-induced decline in blood pressure (BP) of > 10 mmHg may adversely affect cardiac function in HF patients, offsetting the benefits of rate control (32))</p> <ul style="list-style-type: none"> • HF patients are at increased risk of adverse effects from antiarrhythmic drugs, and the agents available to maintain sinus rhythm are limited in the presence of HF (33-35) • Amiodarone and dofetilide are the only guideline-recommended antiarrhythmic agents for this patient population (36) However <ul style="list-style-type: none"> ○ Their use is limited by significant drug-drug interactions and adverse effects (37) ○ Long-term use of amiodarone carries risks of significant pulmonary, hepatic, and thyroid toxicity and is associated with symptomatic bradycardia requiring pacemaker implantation (37) • Dronedarone is contraindicated in HF as it is associated with an increased mortality in patients with HF NYHA class IV and NYHA classes II-III (38) • Flecainide may increase the risk of ventricular arrhythmias in impaired left ventricular function and may worsen HF (39) • Ablation and pacing are an effective method to achieve rate control, but prolonged right ventricular pacing may

Co-morbidity	Prevalence & Impact on heart failure (HF)	Management Options	Clinical Caveats & Considerations
Cognitive impairment (including dementia)	<ul style="list-style-type: none"> • Thirty to 80% of patients with HF experience some degree of cognitive impairment (CI) (40, 41) • The aetiology of CI is heterogeneous and it can be promoted or caused by numerous somatic factors. Relevant somatic factors include hypertension, diabetes mellitus, HF, chronic obstructive airways disease and bronchial asthma. CI may be facilitated by hypercholesterolemia, chronic renal failure, and hypothyroidism (42, 43) • The severity of CI parallels that of CHF (44) • HF patients with severe forms of CI are older, have less formal education, and have significantly more comorbidities. For example, depressed patients have twice the odds of being impaired in the cognitive domains of executive function, processing speed, and memory (odds ratio 1.98, 95% CI 1.08-3.64) (45) • HF negatively impacts multiple aspects of cognitive functioning, including attention, working memory, learning ability and delay recall, executive function, and psychomotor speed (40, 41, 46) • Higher BMI is associated with CI in those with HF. In particular, declines in attention and executive functioning have been found in men but not women (47) • Mild CI lowers self-efficacy in self-care management (48) • HF patients with CI fail to recognize early symptoms and make appropriate self-care decisions (49), have difficulty with adherence to medication management (44, 50), and are less likely to participate in out-patient treatment programs resulting in worse 	<ul style="list-style-type: none"> • ACE inhibitors, cardiotonic medication (such as digoxin), and antiarrhythmic drugs improve cognitive performance (54) • Physical activity positively impacts upon cognitive performance (55) • Structured cognitive training programs have been shown to improve working and general memory, psychomotor speed, executive function (56) • Cardiac resynchronisation therapy produces significant short-term improvements in executive and visuospatial functioning (57) • Cardiac resynchronisation therapy has also been shown to improve neurocognitive (attention, information processing, and controlled oral word processing), and psychosocial functioning in patients by increasing cardiac output and cerebral perfusion. However, further testing is required as this study comprised a small sample (n=20) (58) • Enhanced external counter-pulsation therapy significantly improves cognitive domains including spontaneous naming, attention, and executive functioning (59) • A nurse-based out-patient clinic intervention led to significant improvements on the Mini-Mental Status tool in females with HF at 6-months when compared to standard care (60) 	<ul style="list-style-type: none"> • No reported contraindications or side effects of any of the interventions outlined to the left - with the exception of reduced adherence over time (54, 55, 57, 61)

Co-morbidity	Prevalence & Impact on heart failure (HF)	Management Options	Clinical Caveats & Considerations
	<p>clinical outcomes (51)</p> <ul style="list-style-type: none"> • These patients are at increased risk of HF decompensation, unplanned hospital admissions and mortality (52) • CI is associated with a sixfold increase in functional disability (OR: 6.49; 95% C.I. 4.39–9.59) independent of potential confounders including age, sex, hypotension, comorbidities and medication (53) 		
Depression/Anxiety	<ul style="list-style-type: none"> • Clinical depression is extremely common in HF (62) • It is associated with increased hospitalisations and mortality (63-67) • Comorbid depression has been reported to be a predictor of cardiac events (62, 68) 	<ul style="list-style-type: none"> • Selective serotonin reuptake inhibitor (SSRI) Sertraline (anti-depressant) is no more effective than placebo in reducing depressive symptoms and improving cardiovascular status in HF patients (69) • Previous RCTs have shown that sertraline and citalopram are first line SSRIs for improving depression symptoms in those with CHD (70, 71) • Cognitive behavioural therapy (CBT) is effective in improving depressive symptoms in those with CHD (72) • CBT is advocated to prevent readmission and to achieve remission of moderate to severe depression in those with CHD (73, 74) • Cardiac rehabilitation has been found to reduce depressive symptoms and improve cardiac fitness (75) 	<ul style="list-style-type: none"> • No adverse effects from SSRI usage • Patients may not be compliant • Patients may not be able to tolerate anti-depressants • Tricyclic antidepressants and monoamine oxidase inhibitors are contraindicated for many patients with heart disease because of their cardiotoxic side effects (76)
Diabetes (Type 2) and other related conditions including obesity/ metabolic syndrome	<ul style="list-style-type: none"> • Type 2 diabetes is a common comorbidity in HF and the two diseases are interrelated (77, 78) • Approximately 1/3 of patients with HF have Type 2 Diabetes (78) • According to the most recent evidence, the prevalence of comorbid HF among those with diabetes in individuals > 65 years is 	<ul style="list-style-type: none"> • Metformin is the most commonly prescribed oral glucose lowering therapy and is the first-line agent for treating Type 2 diabetes in the setting of HF (83) • Metformin improves insulin sensitivity by enhancing peripheral glucose uptake and reducing hepatic glucose production (83) • Associated with lower mortality and re- 	<ul style="list-style-type: none"> • Metformin poses a risk of lactic acidosis but can be safely used in patients with normal renal function, stable hemodynamic, and mild-moderate LV dysfunction (83, 94) • TZD's should be stopped in those with symptomatic HF as they cause fluid retention and increase the risk of

Co-morbidity	Prevalence & Impact on heart failure (HF)	Management Options	Clinical Caveats & Considerations
	<p>1.5%-2%. Moreover, this is expected to increase exponentially in the upcoming decades (79)</p> <ul style="list-style-type: none"> • Diabetes is associated with higher risks for both all-cause and HF-related preventable hospitalisation and re-hospitalisations(80) • The presence of HF in patients with diabetes confers a ten-fold increase in mortality and a 5-year survival rate of only 12.5% (81) • The risk of mortality is the same for both ischemic (HFReEF) and non-ischemic (typically HFpEF) patients with HF (82) • Evidence for the use of commonly used drugs (i.e. metformin, sulfonylureas and insulin) comes from registries, observational data and subgroup analysis • Prospective randomised trials of the optimal glucose-lowering therapies in glucose-lowering strategy in patients with diabetes and HF are needed • Due to the adverse cardiovascular effects observed with the TZDs, the FDA has mandated that new diabetes drugs undergo cardiovascular outcomes trials 	<p>hospitalisation (84-87)</p> <ul style="list-style-type: none"> • Has been associated with reducing myocardial infarction (MI) size in patients presenting with ST-elevation myocardial infarction (STEMI) (88) • Recommendations on the use of sulphonylureas in HFare based on observational studies. It remains unclear whether or not sulfonylureas are associated with increased CV risk. • There is controversy on the use of the thiazolidinediones (TZD), insulin-sensitizing medications in those with diabetes mellitus and HF. TZDs cause sodium retention and plasma volume expansion which can worsen HF and increase HF hospitalisation. The ESC guidelines discourage the use of TZDs in patients with diabetes and HF (89) • Glitazones (eg rosiglitazone and Pioglitazone) may also be prescribed • The use of pioglitazone to treat diabetes in those with CVD has shown mixed results. One study reported that this drug has good long-term tolerability with low adverse effects (90); however, others have reported pioglitazone induced significant increases in natriuretic peptides and alterations of cardiac size (91) and increased hospitalisations (92) <ul style="list-style-type: none"> ○ Rosiglitazone has been recommended over pioglitazone to improve myocardial systolic function (93) 	<p>hospitalisation (78, 87)</p> <ul style="list-style-type: none"> • Sulphonylureas increase BMI (95) • The use of insulin in HF is controversial – tight glycaemic control improves survival in advanced HF, but overall, insulin-treated HF patients have significantly worse prognosis(96) • In addition, insulin increases BMI (96) • Use of saxagliptin [selective dipeptidyl peptidase-4 (DPP-4)] inhibitor confers no overall benefit when compared to placebo and associated with a higher risk of hospitalisation for HF when followed-up over 2-years (97, 98) • A trend towards increased risk of hospital admissions for HF [relative risk (RR) 1.30, 95% CI 0.35–4.82] and all-cause mortality (HR 1.50, 95% CI 0.49–4.59) has been associated with rosiglitazone treatment (99), however more long-term studies are required. One 52-week, study found that rosiglitazone improved glycaemic control and did not adversely affect LVEF in patients with CHF (100) • Pioglitazone is associated with a higher rate of HF hospitalisations (92)
Musculoskeletal disorders	<ul style="list-style-type: none"> • Musculoskeletal disorders such as osteoporosis and osteopenia, osteoarthritis (OA), and rheumatoid arthritis (RA) are common comorbidities in patients with HF, particularly due to the increased prevalence of both in older populations 	<ul style="list-style-type: none"> • Optimal treatment of CHF with osteoporosis is to increase vitamin D, calcium and improve physical activity levels (104) • Topical non-steroidal creams, capsaicin, topical lidocaine, intra-articular therapies, and judicious use of narcotics are also 	<ul style="list-style-type: none"> • Avoid use of NSAIDs wherever possible due to risk of sodium and water retention, peripheral vasoconstriction and increased

Co-morbidity	Prevalence & Impact on heart failure (HF)	Management Options	Clinical Caveats & Considerations
	<ul style="list-style-type: none"> • Mortality at 1-year following HF is higher in those with RA when compared to those without RA (35% versus 19%; multivariable hazard ratio 1.89, 95% confidence interval 1.26-2.84) (101) • Severe functional disability/frailty is present in >50% of patients admitted to hospital for HF (102) • Pre-admission functional status is a predictor of short-term mortality in those with HF (102) • Frailty occurs in 15-74% of HF patients (depending on the study population and assessment method(s)) (103) • Those with HF have lower bone mineral density-Z (BMD-Z) scores. HF patients also have lower vitamin D levels and physical performance scores, higher fragility marker scores and inflammatory markers (TNF-α) (104) • There is a significant association between fragility marker scores and ejection fraction (104) • HF is associated with a 30% increase in fractures independent of risk factors associated with BMD (105, 106) • Increased bone resorption due to renal insufficiency with consecutive secondary hyperparathyroidism are the main causes for BMD loss in CHF (107) • Among hip fracture patients, the main risk factors for in-hospital mortality were advancing age, male gender, HF and liver disease (108) • Among hip and knee OA patients, severity of OA disability is associated with a significant increase in all-cause mortality and serious CVD adverse events after controlling for multiple confounders (109) 	<p>advocated as they do not negatively impact on HF (111)</p> <ul style="list-style-type: none"> • Osteopenia and osteoporosis in HF should be managed with a combination of vitamin D and calcium supplementation, bisphosphonates, and non-aerobic weight-bearing exercises (107) • Frailty and functional deficits should be managed with balance and strength training to prevent decline in physical function (112) • Aerobic or resistance training has been shown to lead to improved physical performance and health-related quality of life (HRQoL) and may increase the probability of older adults remaining independent (113), with home-based exercise programs shown to be as effective as supervised exercise programs. (114, 115) 	<p>severity of HF (116)</p> <ul style="list-style-type: none"> • When NSAIDs are used, naproxen is preferred; avoid ibuprofen due to its blood-thinning properties and the increased risk of cardiovascular events (117, 118) • Patients taking ≥ 2 anti-inflammatories were found to have of N-terminal pro-B-type natriuretic peptide values of ≥ 100 ng/L (NT-proBNP). This is significantly associated with a 3.7-fold higher risk for cardiovascular-related adverse events (119-121). Patients with a NT-proBNP level below 100 pg/ml had a 0.94% rate of thrombotic events or HF at 2-years (121) • Corticosteroids should also be used with caution as they can worsen HF via sodium and water retention (39, 122) • At high doses, corticosteroids may also cause arrhythmias (123) • TNF antagonists (e.g. infliximab, etanercept) should be avoided in RA patients with HF as they increase LVEF (124) and BP levels (125) • A 2011 systematic review (n=20

Co-morbidity	Prevalence & Impact on heart failure (HF)	Management Options	Clinical Caveats & Considerations
	<ul style="list-style-type: none"> Acute myocardial infarction (AMI) patients with RA receiving similar treatment with reperfusion therapy and cardio protective medications were found to have similar short-term outcomes compared to patients without RA. AMI patients with RA, however, had poorer long-term outcomes which included mortality and recurrent MI (110) 		<p>articles) found that TNF antagonists do not increase the risk of HF (126)</p>
Renal	<ul style="list-style-type: none"> Renal dysfunction is present in 35–50% of 	<ul style="list-style-type: none"> Clinical guidelines routinely recommend the 	<ul style="list-style-type: none"> ACE inhibitors and ARBs are

Co-morbidity	Prevalence & Impact on heart failure (HF)	Management Options	Clinical Caveats & Considerations
<p>impairment/disease</p>	<p>CHF patients and is often chronic in nature (127)</p> <ul style="list-style-type: none"> • It is consistently an independent marker of adverse outcome in HF (127, 128) • HF mortality is significantly higher in patients with baseline renal impairment (129, 130) • Renal impairment can range from reversible ischemic damage to renal failure requiring short- or long-term renal replacement therapy (131) 	<p>use of ACE inhibitors or ARBs to treat patients with comorbid renal and cardiac diseases (132)</p> <ul style="list-style-type: none"> • The ARB valsartan effectively reduces glomerular filtration rate and morbidity in those with HF and Chronic Kidney Disease (CKD)-The Valsartan in Heart Failure RCT (Val-HeFT) (133) • Beta blockers provide benefits in HF and renal dysfunction with no contraindications (134) • Vasopressin antagonists may improve fluid retention, hyponatremia and renal dysfunction in HF, but further research is needed into long-term benefits and contraindications (135) • There is limited evidence regarding the benefits of Implantable Cardioverter Defibrillator (ICD) therapy for patients with HF and renal dysfunction, but there do not appear to be contraindications (136, 137) • Cardiac resynchronisation therapy may provide the largest survival benefit in HF patients with moderate renal impairment by improving glomerular filtration rate and left ventricular function (138) • A recent systematic review revealed that resynchronisation therapy increased survival rates in patients with CHF and chronic kidney disease, compared with other modalities of treatment (medical therapy or ICD alone) (139) • Levosimendan has been shown to have an immediate reno-protective effect in patients with HF. This is mediated by an increase in renal blood flow, due to a selective renal arterial and venous vasodilating action (140, 141) • In HFrEF. renin-angiotensin receptor 	<p>contraindicated in patients with a history of angioedema (143).</p> <ul style="list-style-type: none"> • If renal function deteriorates to a significant degree (e.g. 25% increase in serum creatinine or 15% decrease in eGFR), the risk benefit effect of treatment should be re-evaluated (144) • Valsartan is safe and well-tolerated in those with stable to moderate HF (133, 145) • Nesiritide should not be used in patients with concurrent renal impairment as it is associated with an increased risk of mortality (146)

Co-morbidity	Prevalence & Impact on heart failure (HF)	Management Options	Clinical Caveats & Considerations
		(RAS) antagonists reduced mortality. In 602 elderly patients RAS antagonist use was associated with 55% [95% CI 51–59] vs. 45% (41–49) 1-year survival, P= 0.001, with a HR for mortality of 0.76 (95% CI 0.67–0.86, P=0.001) (142)	
Respiratory disease/dyspnoea	<ul style="list-style-type: none"> • Dyspnoea is a key primary symptom and clinical trial endpoint in acute HF, yet objective assessment is lacking (147) • Dyspnoea is difficult to measure in clinical trials due to its subjective nature and the absence of a validated, gold standard assessment tool (147) • Patients with dyspnoea and HF are extremely physically inactive and are even unable to perform an exercise test. They are at a greater risk of poorer clinical outcomes and mortality (148) • Up to 1/3 of HF out-patients have comorbid chronic obstructive pulmonary disease (COPD) (149) • The symptoms of HF and COPD overlap significantly to the extent that the two disorders are difficult to distinguish symptomatically (150) 	<ul style="list-style-type: none"> • Sildenafil may be useful for dyspnoea in CHF due to reduction of peripheral muscle signalling (151) • Some evidence supports the use of exercise training and mindfulness-based programs for dyspnoea in HF (151) • Bronchodilators (a first-line COPD treatment) have not been systematically evaluated in HF (due to exclusion of HF patients from RCT's), so although there is no evidence for contraindication • Anticholinergics are the preferred option until further evidence is obtained (152) • In HF patients with COPD, a long-acting anticholinergic is recommended (152) • Inhaled steroids are also effective and safe for COPD in HF patients (152) • Bilevel positive airway pressure ventilation improved outcomes (re-hospitalisations and mortality) in those with COPD and acute decompensated HF (153) • IV furosemide (diuretic treatment) administered over a 3-day period in hospitalised CHF patients is effective in significantly reducing fluid, improving breathlessness and reducing re-hospitalisations (154) • Oxygen therapy is no more effective than normal breathing in those with dyspnoea and cardiac conditions (155) 	<ul style="list-style-type: none"> • Oral steroids can cause sodium and fluid retention and thus should be used with caution for COPD in HF patients (152) • Bronchodilator is not recommended for non-COPD dyspnoea in acute heart failure as it has been associated with worse clinical outcomes (156) • IV furosemide is safe and effective for use in CHF patients (154) • Bilevel positive airway pressure ventilation is non-invasive and well-tolerated in HF patients with COPD (153)

Co-morbidity	Prevalence & Impact on heart failure (HF)	Management Options	Clinical Caveats & Considerations
<p>Sleep-disordered breathing (obstructive and/or central sleep apnoea)</p>	<ul style="list-style-type: none"> • Common in both predominant forms HF (157) -[HFrEF (157) and HFpEF (158)] • Comorbid sleep-disordered breathing may take the form of either Obstructive sleep apnoea (OSA) or Cheyne-Stokes respiration-central sleep apnoea (CSA) and is frequently accompanied by a poor prognosis (159-162) • OSA is an independent risk factor for hypertension, CHF, and pulmonary hypertension (159, 162) • Patients with CSA have advanced symptoms and more impaired cardiovascular function than those without central sleep apnoea (158) • CSA affects cardiovascular function adversely by causing tissue hypoxia, arousals from sleep, and activation of the sympathetic nervous system • CSA independently increases the risk of death (163) • Sleep-disordered breathing may contribute to disease progression (164) 	<ul style="list-style-type: none"> • Cardioverter-defibrillator therapies (157) • Continuous positive airway pressure (CPAP) therapy (160, 165) is associated with: <ul style="list-style-type: none"> ○ Improved nocturnal oxygenation ○ Increased LVEF (only when the treatment reduces the apnoea – hypopnea index), ○ Lower norepinephrine levels ○ Increased exercise capacity (6MWT) (166) ○ Reduced systolic BP ○ Improved left ventricular systolic function (167) ○ Reduced hospital readmission and ED visits 30-days after discharge (168) • CPAP does not impact on survival rates (166) • Surgical valve repair improves cardiac function and CSA (169) • Auto-servoventilation (ASV) has been found to significantly improve CSA to a greater extent than CPAP in those with HF (170-177) • ASV acts as an anti-inflammatory and is an important contributor to reductions in cardiac events (178) • Randomised studies with large sample sizes evaluating non-pharmacological nursing interventions that improve sleep are required (179) • Biventricular stimulation decreases CSA and improves quality of sleep and daytime sleepiness in patients with CHF (180) • A 6-month aerobic exercise program improved sleep apnoea in patients with CHF (181) 	<ul style="list-style-type: none"> • No adverse side effects (164, 177) • Poor patient tolerability (164) • Poor patient compliance (164) • The SERVE-HF trial, a multinational, multicentre, randomised, parallel trial designed to assess the effects of addition of Adaptive servo-ventilation (PaceWave™, AutoSet CS™; ResMed) for the treatment of sleep apnoea in those with HF. This trial was found to increase mortality in those with symptomatic HF. The SERVE-HF trial was only conducted in HFrEF not HFpEF and was restricted to those with predominantly central sleep in sleep apnoea. The results of this trial led to no changes in standard care treatment for those with OSA (182)

Co-morbidity	Prevalence & Impact on heart failure (HF)	Management Options	Clinical Caveats & Considerations
Thyroid Disease	<ul style="list-style-type: none"> • Untreated overt hyperthyroidism and hypothyroidism have been reported as common causes of HF (183) • Recent estimates suggest that approximately 10% of HF patients have comorbid thyroid disease (184) • Hypothyroidism is more prevalent in men than women (185) • Thyroid dysfunction is a key risk factor for HF development (186) • A retrospective study (1969-2002) with a mean 9-year follow-up found that the rate of cardiovascular-related hospitalisations was significantly higher in those with hyperthyroidism when compared to controls [637.1 vs. 476.4 per 10 000 person-years, rate ratio (RR) 1.12, 95% CI 1.03-1.21] (187) • Surgically treated hyperthyroidism still increases the risk of hospitalisation due to CVD (up to 2 decades after effective surgical treatment) (188) • Thyroid Stimulating Hormone (TSH) levels above normal are independently associated with increased mortality and cardiac-related hospitalisations (186) • Risks for cardiac events in HF patients are increased with both low and high levels of TSH (TSH \geq10 and $<$0.10 mIU/L) (189) 	<ul style="list-style-type: none"> • Treatment with levothyroxine normalizes TSH levels (186) • Treatment with replacement doses of L-T4 reduces myocyte apoptosis and improves cardiovascular performance in mild and subclinical hypothyroidism (190) • Definitive treatment of hyperthyroidism with anti-thyroid drugs (l-radioiodine) is usually recommended to recover cardiac function (191) • Some studies suggest that replacement doses of triiodothyronine (T3) may improve cardiovascular remodelling and function in patients with HF and low T3 syndrome (173) • Treatment with β-adrenergic blockade is first-line therapy to reduce heart rate in cardio-toxic thyroid patients (191) • In thyroid patients with overt HF involving pulmonary congestion, treatment with digitalis and diuretics is appropriate (192) • Radioactive Iodine for hyperthyroidism increases the risk of cardiovascular related morbidity and this risk lasts up to 35-years (187) • Cardiac resynchronisation therapy (CRT) is associated with a worse prognosis of hypothyroidism (193) 	<ul style="list-style-type: none"> • l-radioiodine is both safe and effective especially when used in conjunction with β-adrenergic blockade (194) • However, a trend towards increased cardiac mortality has been reported in treated hyperthyroid patients (195)

Review References:

Review References:

1. Anand IS, Kuskowski MA, Rector TS, Florea VG, Glazer RD, Hester A, et al. Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT. *Circulation*. 2005;112(8):1121-7.
2. Avni T, Leibovici L, Gafter-Gvili A. Iron supplementation for the treatment of chronic heart failure and iron deficiency: systematic review and meta-analysis. *Eur J Heart Fail*. 2012;14(4):423-9.
3. Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R, et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. *N Engl J Med*. 2013;368(13):1210-9.
4. Fink AM, Sullivan SL, Zerwic JJ, Piano MR. Fatigue with systolic heart failure. *J Cardiovasc Nurs*. 2009;24(5):410-7.
5. Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R, et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. *N Engl J Med*. 2013;368(13):1210-9.
6. Beck-da-Silva L, Piardi D, Soder S, Rohde LE, Pereira-Barretto AC, de Albuquerque D, et al. IRON-HF study: a randomized trial to assess the effects of iron in heart failure patients with anemia. *Int J Cardiol*. 2013;168(4):3439-42.
7. Grigorian Shamagian L, Varela Roman A, Garcia-Acuña JM, Mazon Ramos P, Virgos Lamela A, Gonzalez-Juanatey JR. Anaemia is associated with higher mortality among patients with heart failure with preserved systolic function. *Heart*. 2006;92(6):780-4.
8. Nanas JN, Matsouka C, Karageorgopoulos D, Leonti A, Tsolakis E, Drakos SG, et al. Etiology of anemia in patients with advanced heart failure. *J Am Coll Cardiol*. 2006;48(12):2485-9.
9. Pisaniello AD, Wong DTL, Kajani I, Robinson K, Shakib S. Anaemia in chronic heart failure: more awareness is required. *Intern Med J*. 2013;43(9):999-1004.
10. Androne AS, Katz SD, Lund L, LaManca J, Hudaihed A, Hryniewicz K, et al. Hemodilution is common in patients with advanced heart failure. *Circulation*. 2003;107(2):226-9.
11. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. *N Engl J Med*. 2009;361(25):2436-48.
12. Cohen-Solal A, Damy T, Terbah M, Kerebel S, Baguet J-P, Hanon O, et al. High prevalence of iron deficiency in patients with acute decompensated heart failure. *Eur J Heart Fail*. 2014;16(9):984-91.
13. Fox MT, Jorde UP. Anemia, chronic heart failure, and the impact of male vs. female gender. *Congest Heart Fail*. 2005;11(3):129-32.
14. Darbapoetin alfa does not help adults with heart failure and anaemia. *BMJ*. 2013;346:f1626.
15. Qaseem A, Humphrey LL, Fitterman N, Starkey M, Shekelle P. Treatment of anemia in patients with heart disease: a clinical practice guideline from the American College of Physicians. *Ann Intern Med*. 2013;159(11):770-9.
16. Robles NR, Macias JF, Herrera J. Erythropoiesis stimulating agents (ESAs) for congestive heart failure: the red and the black. *Eur J Intern Med*. 2014;25(2):193-6.
17. Bolger AP, Bartlett FR, Penston HS, O'Leary J, Pollock N, Kaprielian R, et al. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. *J Am Coll Cardiol*. 2006;48(6):1225-7.
18. Filippatos G, Farmakis D, Colet JC, Dickstein K, Lüscher TF, Willenheimer R, et al. Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial. *Eur J Heart Fail*. 2013;15(11):1267-76.
19. Komajda M, Anker SD, Charlesworth A, Okonko D, Metra M, Di Lenarda A, et al. The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. *Eur Heart J*. 2006;27(12):1440-6.
20. Ghali JK, Anand IS, Abraham WT, Fonarow GC, Greenberg B, Krum H, et al. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. *Circulation*. 2008;117(4):526-35.
21. Abraham WT, Anand IS, Klapholz M, Ponikowski P, Scarlata D, Wasserman SM, et al. Treatment of anemia with darbepoetin alfa in heart failure. *Congest Heart Fail*. 2010;16(3):87-95.
22. Cleland JGF, Sullivan JT, Ball S, Horowitz JD, Agoram B, Rosser D, et al. Once-monthly administration of darbepoetin alfa for the treatment of patients with chronic heart failure and anemia: a pharmacokinetic and pharmacodynamic investigation. *J Cardiovasc Pharmacol*. 2005;46(2):155-61.
23. Klapholz M, Abraham WT, Ghali JK, Ponikowski P, Anker SD, Knusel B, et al. The safety and tolerability of darbepoetin alfa in patients with anaemia and symptomatic heart failure. *Eur J Heart Fail*. 2009;11(11):1071-7.

24. Aronson D, Dann EJ, Bonstein L, Blich M, Kapeliovich M, Beyar R, et al. Impact of red blood cell transfusion on clinical outcomes in patients with acute myocardial infarction. *Am J Cardiol.* 2008;102(2):115-9.
25. Baczko I, Lepran I, Kiss L, Muntean DM, Light PE. Future perspectives in the pharmacological treatment of atrial fibrillation and ventricular arrhythmias in heart failure. *Curr Pharm Des.* 2015;21(8):1011-29.
26. Lubitz SA, Rosen AB, Ellinor PT, Benjamin EJ. Stroke risk in AF: do AF patterns matter? *Eur Heart J.* 2010;31(8):908-10.
27. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). *Eur Heart J.* 2008;29(19):2388-442.
28. Aagaard P, Di Biase L, Natale A. Ablation of atrial arrhythmias in heart failure. *Heart Fail Clin.* 2015;11(2):305-17.
29. Zimetbaum P. Antiarrhythmic drug therapy for atrial fibrillation. *Circulation.* 2012;125(2):381-9.
30. Doshi RN, Daoud EG, Fellows C, Turk K, Duran A, Hamdan MH, et al. Left ventricular-based cardiac stimulation post AV nodal ablation evaluation (the PAVE study). *J Cardiovasc Electrophysiol.* 2005;16(11):1160-5.
31. Lechat P. [Beta-blockers and new drugs for cardiac failure]. *Rev Prat.* 1997;47(19):2131-4.
32. Lechat P, Hulot JS, Escolano S, Mallet A, Leizorovicz A, Werhlen-Grandjean M, et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. *Circulation.* 2001;103(10):1428-33.
33. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. *Circulation.* 1990;82(4):1106-16.
34. Flaker GC, Blackshear JL, McBride R, Kronmal RA, Halperin JL, Hart RG. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. *J Am Coll Cardiol.* 1992;20(3):527-32.
35. Stevenson WG, Stevenson LW, Middlekauff HR, Fonarow GC, Hamilton MA, Woo MA, et al. Improving survival for patients with atrial fibrillation and advanced heart failure. *J Am Coll Cardiol.* 1996;28(6):1458-63.
36. Wann LS, Curtis AB, January CT, Ellenbogen KA, Lowe JE, Estes NA, 3rd, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation.* 2011;123(1):104-23.
37. Trulock KM, Narayan SM, Piccini JP. Rhythm control in heart failure patients with atrial fibrillation: contemporary challenges including the role of ablation. *J Am Coll Cardiol.* 2014;64(7):710-21.
38. National Heart Foundation. Guidelines for the prevention, detection and management of chronic heart failure in Australia. Australia: National Heart Foundation of Australia, 2011.
39. Rossi S e. Australian Medicines Handbook. Adelaide: eAMH [online]; 2012.
40. Vogels RL, Oosterman JM, van Harten B, Scheltens P, van der Flier WM, Schroeder-Tanka JM, et al. Profile of cognitive impairment in chronic heart failure. *J Am Geriatr Soc.* 2007;55(11):1764-70.
41. Vogels RL, Scheltens P, Schroeder-Tanka JM, Weinstein HC. Cognitive impairment in heart failure: a systematic review of the literature. *Eur J Heart Fail.* 2007;9(5):440-9.
42. Etgen T, Brönnner M, Sander D, Bickel H, Sander K, Förstl H. [Somatic factors in cognitive impairment]. *Fortschr Neurol Psychiatr.* 2009;77(2):72-82.
43. Miller LA, Spitznagel MB, Alosco ML, Cohen RA, Raz N, Sweet LH, et al. Cognitive profiles in heart failure: a cluster analytic approach. *J Clin Exp Neuropsychol.* 2012;34(5):509-20.
44. Debette S, Bauters C, Leys D, Lamblin N, Pasquier F, de Groote P. Prevalence and determinants of cognitive impairment in chronic heart failure patients. *Congest Heart Fail.* 2007;13(4):205-8.
45. Levin SN, Hajduk AM, McManus DD, Darling CE, Gurwitz JH, Spencer FA, et al. Cognitive status in patients hospitalized with acute decompensated heart failure. *Am Heart J.* 2014;168(6):917-23.
46. Gallagher R, Sullivan A, Burke R, Hales S, Gillies G, Cameron J, et al. Mild cognitive impairment, screening, and patient perceptions in heart failure patients. *J Card Fail.* 2013;19(9):641-6.
47. Hawkins MAW, Gunstad J, Dolansky MA, Redle JD, Josephson R, Moore SM, et al. Greater body mass index is associated with poorer cognitive functioning in male heart failure patients. *J Card Fail.* 2014;20(3):199-206.

48. Cameron J, Worrall-Carter L, Page K, Riegel B, Lo SK, Stewart S. Does cognitive impairment predict poor self-care in patients with heart failure? *Eur J Heart Fail.* 2010;12(5):508-15.
49. Lee CS, Gelow JM, Bidwell JT, Mudd JO, Green JK, Jurgens CY, et al. Blunted responses to heart failure symptoms in adults with mild cognitive dysfunction. *J Cardiovasc Nurs.* 2013;28(6):534-40.
50. Alosco ML, Spitznagel MB, van Dulmen M, Raz N, Cohen R, Sweet LH, et al. Cognitive function and treatment adherence in older adults with heart failure. *Psychosom Med.* 2012;74(9):965-73.
51. Ekman I, Fagerberg B, Skoog I. The clinical implications of cognitive impairment in elderly patients with chronic heart failure. *J Cardiovasc Nurs.* 2001;16(1):47-55.
52. McLennan SN, Pearson SA, Cameron J, Stewart S. Prognostic importance of cognitive impairment in chronic heart failure patients: does specialist management make a difference? *Eur J Heart Fail.* 2006;8(5):494-501.
53. Zuccala G, Pedone C, Cesari M, Onder G, Pahor M, Marzetti E, et al. The effects of cognitive impairment on mortality among hospitalized patients with heart failure. *Am J Med.* 2003;115(2):97-103.
54. Almeida OP, Tamai S. Clinical treatment reverses attentional deficits in congestive heart failure. *BMC Geriatr.* 2001;1:2.
55. Tanne D, Freimark D, Poreh A, Merzeliak O, Bruck B, Schwammenthal Y, et al. Cognitive functions in severe congestive heart failure before and after an exercise training program. *Int J Cardiol.* 2005;103(2):145-9.
56. Pressler SJ, Therrien B, Riley PL, Chou CC, Ronis DL, Koelling TM, et al. Nurse-Enhanced Memory Intervention in Heart Failure: the MEMOIR study. *J Card Fail.* 2011;17(10):832-43.
57. Pressler SJ, Therrien B, Riley PL, Chou C-C, Ronis DL, Koelling TM, et al. Nurse-Enhanced Memory Intervention in Heart Failure: the MEMOIR study. *J Card Fail.* 2011;17(10):832-43.
58. Dixit NK, Vazquez LD, Cross NJ, Kuhl EA, Serber ER, Kovacs A, et al. Cardiac resynchronization therapy: a pilot study examining cognitive change in patients before and after treatment. *Clin Cardiol.* 2010;33(2):84-8.
59. Kozdağ G, Işeri P, Gökçe G, Ertaş G, Aygün F, Kutlu A, et al. Treatment with enhanced external counterpulsation improves cognitive functions in chronic heart failure patients. *Türk Kardiyol Dern Arş.* 2013;41(5):418-28.
60. Karlsson MR, Edner M, Henriksson P, Mejhert M, Persson H, Grut M, et al. A nurse-based management program in heart failure patients affects females and persons with cognitive dysfunction most. *Patient Educ Couns.* 2005;58(2):146-53.
61. Carles S, Jr., Curnier D, Pathak A, Roncalli J, Bousquet M, Garcia J-L, et al. Effects of short-term exercise and exercise training on cognitive function among patients with cardiac disease. *J Cardiopulm Rehabil Prev.* 2007;27(6):395-9.
62. Rutledge T, Linke SE, Krantz DS, Johnson BD, Bittner V, Eastwood JA, et al. Comorbid depression and anxiety symptoms as predictors of cardiovascular events: results from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE) study. *Psychosom Med.* 2009;71(9):958-64.
63. Rutledge T, Reis VA, Linke SE, Greenberg BH, Mills PJ. Depression in heart failure: a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. *J Am Coll Cardiol.* 2006;48(8):1527-37.
64. Sherwood A, Blumenthal JA, Hinderliter AL, Koch GG, Adams KF, Jr., Dupree CS, et al. Worsening depressive symptoms are associated with adverse clinical outcomes in patients with heart failure. *J Am Coll Cardiol.* 2011;57(4):418-23.
65. Sherwood A, Blumenthal JA, Trivedi R, Johnson KS, O'Connor CM, Adams KF, Jr., et al. Relationship of depression to death or hospitalization in patients with heart failure. *Arch Intern Med.* 2007;167(4):367-73.
66. Song EK, Lennie TA, Moser DK. Depressive symptoms increase risk of rehospitalisation in heart failure patients with preserved systolic function. *J Clin Nurs.* 2009;18(13):1871-7.
67. Zaya M, Phan A, Schwarz ER. Predictors of re-hospitalization in patients with chronic heart failure. *World J Cardiol.* 2012;4(2):23-30.
68. Rutledge T, Reis SE, Olson MB, Owens J, Kelsey SF, Pepine CJ, et al. Depression symptom severity and reported treatment history in the prediction of cardiac risk in women with suspected myocardial ischemia: The NHLBI-sponsored WISE study. *Arch Gen Psychiatry.* 2006;63(8):874-80.
69. O'Connor CM, Jiang W, Kuchibhatla M, Silva SG, Cuffe MS, Callwood DD, et al. Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. *J Am Coll Cardiol.* 2010;56(9):692-9.
70. Lesperance F, Frasere-Smith N, Koszycki D, Laliberte MA, van Zyl LT, Baker B, et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the

- Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. *JAMA*. 2007;297(4):367-79.
71. Lichtman JH, Bigger JT, Jr., Blumenthal JA, Frasure-Smith N, Kaufmann PG, Lesperance F, et al. Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Psychiatric Association. *Circulation*. 2008;118(17):1768-75.
 72. Lett HS, Davidson J, Blumenthal JA. Nonpharmacologic treatments for depression in patients with coronary heart disease. *Psychosom Med*. 2005;67 Suppl 1:S58-62.
 73. Berkman LF, Blumenthal J, Burg M, Carney RM, Catellier D, Cowan MJ, et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICH) Randomized Trial. *JAMA*. 2003;289(23):3106-16.
 74. Thase ME, Friedman ES, Biggs MM, Wisniewski SR, Trivedi MH, Luther JF, et al. Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. *Am J Psychiatry*. 2007;164(5):739-52.
 75. Milani RV, Lavie CJ. Impact of cardiac rehabilitation on depression and its associated mortality. *Am J Med*. 2007;120(9):799-806.
 76. Glassman A, Shapiro PA, Ford DE, Culpepper L, Finkel MS, Swenson JR, et al. Cardiovascular health and depression. *J Psychiatr Pract*. 2003;9(6):409-21.
 77. Khan SS, Butler J, Gheorghide M. Management of comorbid diabetes mellitus and worsening heart failure. *JAMA*. 2014;311(23):2379-80.
 78. Leung AA, Eurich DT, Lamb DA, Majumdar SR, Johnson JA, Blackburn DF, et al. Risk of heart failure in patients with recent-onset type 2 diabetes: population-based cohort study. *J Card Fail*. 2009;15(2):152-7.
 79. Bonow RO, Gheorghide M. The diabetes epidemic: a national and global crisis. *Am J Med*. 2004;116 Suppl 5A:2S-10S.
 80. Eby E, Hardwick C, Yu M, Gelwicks S, Deschamps K, Xie J, et al. Predictors of 30 day hospital readmission in patients with type 2 diabetes: a retrospective, case-control, database study. *Curr Med Res Opin*. 2015;31(1):107-14.
 81. Bertoni AG, Hundley WG, Massing MW, Bonds DE, Burke GL, Goff DC, Jr. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. *Diabetes Care*. 2004;27(3):699-703.
 82. Andersson C, Weeke P, Pecini R, Kjaergaard J, Hassager C, Køber L, et al. Long-term impact of diabetes in patients hospitalized with ischemic and non-ischemic heart failure. *Scand Cardiovasc J*. 2010;44(1):37-44.
 83. Davoren P. Safe prescribing of metformin in diabetes. *Austr Prescr*. 2014;37(1):2-5.
 84. Aguilar D, Chan W, Bozkurt B, Ramasubbu K, Deswal A. Metformin use and mortality in ambulatory patients with diabetes and heart failure. *Circ Heart Fail*. 2011;4(1):53-8.
 85. Andersson C, Olesen JB, Hansen PR, Weeke P, Norgaard ML, Jørgensen CH, et al. Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study. *Diabetologia*. 2010;53(12):2546-53.
 86. Boyd A, Nawarskas J. Metformin use in decompensated heart failure. *Cardiol Rev*. 2008;16(5):269-72.
 87. Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. *Circulation*. 2005;111(5):583-90.
 88. Lexis CPH, Wieringa WG, Hiemstra B, van Deursen VM, Lipsic E, van der Harst P, et al. Chronic metformin treatment is associated with reduced myocardial infarct size in diabetic patients with ST-segment elevation myocardial infarction. *Cardiovasc Drug Ther*. 2014;28(2):163-71.
 89. Authors/Task Force M, Ryden L, Grant PJ, Anker SD, Berne C, Cosentino F, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). *Eur Heart J*. 2013;34(39):3035-87.
 90. Dormandy J, Bhattacharya M, van Troostenburg de Bruyn A-R. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive. *Drug Saf*. 2009;32(3):187-202.

91. Dorkhan M, Dencker M, Stagmo M, Groop L. Effect of pioglitazone versus insulin glargine on cardiac size, function, and measures of fluid retention in patients with type 2 diabetes. *Cardiovasc Diabetol*. 2009;8:15.
92. Giles TD, Miller AB, Elkayam U, Bhattacharya M, Perez A. Pioglitazone and heart failure: results from a controlled study in patients with type 2 diabetes mellitus and systolic dysfunction. *J Card Fail*. 2008;14(6):445-52.
93. Pala S, Esen O, Akçakoyun M, Kahveci G, Kargin R, Tigen K, et al. Rosiglitazone, but not pioglitazone, improves myocardial systolic function in type 2 diabetic patients: a tissue Doppler study. *Echocardiography*. 2010;27(5):512-8.
94. Shah DD, Fonarow GC, Horwich TB. Metformin therapy and outcomes in patients with advanced systolic heart failure and diabetes. *J Card Fail*. 2010;16(3):200-6.
95. Andersson C, Gislason GH, Jorgensen CH, Hansen PR, Vaag A, Sorensen R, et al. Comparable long-term mortality risk associated with individual sulfonylureas in diabetes patients with heart failure. *Diabetes Res Clin Pract*. 2011;94(1):119-25.
96. Eshaghian S, Horwich TB, Fonarow GC. An unexpected inverse relationship between HbA1c levels and mortality in patients with diabetes and advanced systolic heart failure. *Am Heart J*. 2006;151(1):91.
97. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. *N Engl J Med*. 2013;369(14):1317-26.
98. Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. *Circulation*. 2014;130(18):1579-88.
99. Bach RG, Brooks MM, Lombardero M, Genuth S, Donner TW, Garber A, et al. Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. *Circulation*. 2013;128(8):785-94.
100. Dargie HJ, Hildebrandt PR, Riegger GAJ, McMurray JJV, McMorn SO, Roberts JN, et al. A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure. *J Am Coll Cardiol*. 2007;49(16):1696-704.
101. Davis JM, 3rd, Roger VL, Crowson CS, Kremers HM, Therneau TM, Gabriel SE. The presentation and outcome of heart failure in patients with rheumatoid arthritis differs from that in the general population. *Arthritis Rheum*. 2008;58(9):2603-11.
102. Formiga F, Chivite D, Conde A, Ruiz-Laiglesia F, Franco AG, Bocanegra CP, et al. Basal functional status predicts three-month mortality after a heart failure hospitalization in elderly patients - the prospective RICA study. *Int J Cardiol*. 2014;172(1):127-31.
103. Uchmanowicz I, Łoboz-Rudnicka M, Szelağ P, Jankowska-Polańska B, Łoboz-Grudzień K. Frailty in heart failure. *Curr Heart Fail Rep*. 2014;11(3):266-73.
104. Abou-Raya S, Abou-Raya A. Osteoporosis and congestive heart failure (CHF) in the elderly patient: double disease burden. *Arch Gerontol Geriatr*. 2009;49(2):250-4.
105. Majumdar SR, Ezekowitz JA, Lix LM, Leslie WD. Heart failure is a clinically and densitometrically independent risk factor for osteoporotic fractures: population-based cohort study of 45,509 subjects. *J Clin Endocrinol Metab*. 2012;97(4):1179-86.
106. van Diepen S, Majumdar SR, Bakal JA, McAlister FA, Ezekowitz JA. Heart failure is a risk factor for orthopedic fracture: a population-based analysis of 16,294 patients. *Circulation*. 2008;118(19):1946-52.
107. Frost RJA, Sonne C, Wehr U, Stempfle H-U. Effects of calcium supplementation on bone loss and fractures in congestive heart failure. *Eur J Endocrinol*. 2007;156(3):309-14.
108. Frost SA, Nguyen ND, Black DA, Eisman JA, Nguyen TV. Risk factors for in-hospital post-hip fracture mortality. *Bone*. 2011;49(3):553-8.
109. Hawker GA, Croxford R, Bierman AS, Harvey PJ, Ravi B, Stanaitis I, et al. All-cause mortality and serious cardiovascular events in people with hip and knee osteoarthritis: a population based cohort study. *PLoS One*. 2014;9(3):e91286.
110. McCoy SS, Crowson CS, Maradit-Kremers H, Therneau TM, Roger VL, Matteson EL, et al. Longterm outcomes and treatment after myocardial infarction in patients with rheumatoid arthritis. *J Rheumatol*. 2013;40(5):605-10.
111. Katz JD, Shah T. Persistent pain in the older adult: what should we do now in light of the 2009 American geriatrics society clinical practice guideline? *Pol Arch Med Wewn*. 2009;119(12):795-800.
112. Gary R. Evaluation of frailty in older adults with cardiovascular disease: incorporating physical performance measures. *J Cardiovasc Nurs*. 2012;27(2):120-31.

113. Knocke A. Program description: physical therapy in a heart failure clinic. *Cardiopulm Phys Ther J*. 2012;23(3):46-8.
114. Taylor RS, Dalal H, Jolly K, Moxham T, Zawada A. Home-based versus centre-based cardiac rehabilitation. *Cochrane Database Syst Rev*. 2010(1):CD007130.
115. Dalal HM, Zawada A, Jolly K, Moxham T, Taylor RS. Home based versus centre based cardiac rehabilitation: Cochrane systematic review and meta-analysis. *BMJ*. 2010;340:b5631.
116. Taubert K. Can Patients with Cardiovascular Disease Take Nonsteroidal Antiinflammatory Drugs? *Circulation*. 2008;117:e322-e4.
117. Hopper I. Cardiac effects of non-cardiac drugs. *Austr Prescr*. 2011;34(2):52-4.
118. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. *Eur Heart J*. 2012;33(14):1787-847.
119. Brune K, Katus HA, Moecks J, Spanuth E, Jaffe AS, Giannitsis E. N-terminal pro-B-type natriuretic peptide concentrations predict the risk of cardiovascular adverse events from antiinflammatory drugs: a pilot trial. *Clin Chem*. 2008;54(7):1149-57.
120. Peters MJL, Welsh P, McInnes IB, Wolbink G, Dijkmans BAC, Sattar N, et al. Tumour necrosis factor {alpha} blockade reduces circulating N-terminal pro-brain natriuretic peptide levels in patients with active rheumatoid arthritis: results from a prospective cohort study. *Ann Rheum Dis*. 2010;69(7):1281-5.
121. Ruff CT, Morrow DA, Jarolim P, Ren F, Contant CF, Kaur A, et al. Evaluation of NT-proBNP and high sensitivity C-reactive protein for predicting cardiovascular risk in patients with arthritis taking longterm nonsteroidal antiinflammatory drugs. *J Rheumatol*. 2011;38(6):1071-8.
122. Spieker LE, Ruschitzka FT, Luscher TF, Noll G. The management of hyperuricemia and gout in patients with heart failure. *Eur J Heart Fail*. 2002;4(4):403-10.
123. Myasoedova E, Crowson CS, Nicola PJ, Maradit-Kremers H, Davis JM, 3rd, Roger VL, et al. The influence of rheumatoid arthritis disease characteristics on heart failure. *J Rheumatol*. 2011;38(8):1601-6.
124. Kotyla PJ, Owczarek A, Rakoczy J, Lewicki M, Kucharz EJ, Emery P. Infliximab treatment increases left ventricular ejection fraction in patients with rheumatoid arthritis: assessment of heart function by echocardiography, endothelin 1, interleukin 6, and NT-pro brain natriuretic peptide. *J Rheumatol*. 2012;39(4):701-6.
125. Santos RC, Figueiredo VN, Martins LC, Moraes CdH, Quinaglia T, Boer-Martins L, et al. Infliximab reduces cardiac output in rheumatoid arthritis patients without heart failure. *Rev Assoc Méd Bras*. 2012;58(6):698-702.
126. Westlake SL, Colebatch AN, Baird J, Curzen N, Kiely P, Quinn M, et al. Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. *Rheumatology*. 2011;50(3):518-31.
127. Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, Yusuf S, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. *Circulation*. 2006;113(5):671-8.
128. Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne J. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. *J Card Fail*. 2007;13(6):422-30.
129. Ismailov RM, Goldberg RJ, Lessard D, Spencer FA. Decompensated heart failure in the setting of kidney dysfunction: a community-wide perspective. *Nephron Clin Pract*. 2007;107(4):c147-c55.
130. Iyngkaran P, Thomas M, Majoni W, Anavekar NS, Ronco C. Comorbid Heart Failure and Renal Impairment: Epidemiology and Management. *Cardiorenal Med*. 2012;2(4):281-97.
131. Ronco C, McCullough P, Anker SD, Anand I, Aspromonte N, Bagshaw SM, et al. Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. *Eur Heart J*. 2010;31(6):703-11.
132. Molnar MZ, Kalantar-Zadeh K, Lott EH, Lu JL, Malakauskas SM, Ma JZ, et al. Angiotensin-converting enzyme inhibitor, angiotensin receptor blocker use, and mortality in patients with chronic kidney disease. *J Am Coll Cardiol*. 2014;63(7):650-8.
133. Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, Cohn JN. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure. *Circulation*. 2009;120(16):1577-84.
134. Bakris GL, Hart P, Ritz E. Beta blockers in the management of chronic kidney disease. *Kidney Int*. 2006;70(11):1905-13.
135. Hobbs RE, Tang WH. Vasopressin receptor antagonists in heart failure. *Recent Pat Cardiovasc Drug Discov*. 2006;1(2):177-84.

136. Cheema A, Singh T, Kanwar M, Chilukuri K, Maria V, Saleem F, et al. Chronic kidney disease and mortality in implantable cardioverter-defibrillator recipients. *Cardiol Res Pract.* 2010;2010:989261.
137. Hohnloser SH, Israel CW. Current evidence base for use of the implantable cardioverter-defibrillator. *Circulation.* 2013;128(2):172-83.
138. Adelstein EC, Shalaby A, Saba S. Response to cardiac resynchronization therapy in patients with heart failure and renal insufficiency. *Pacing Clin Electrophysiol.* 2010;33(7):850-9.
139. Garg N, Thomas G, Jackson G, Rickard J, Nally JV, Jr., Tang WH, et al. Cardiac resynchronization therapy in CKD: a systematic review. *Clin J Am Soc Nephrol.* 2013;8(8):1293-303.
140. Fedele F, Bruno N, Brasolin B, Caira C, D'Ambrosi A, Mancone M. Levosimendan improves renal function in acute decompensated heart failure: possible underlying mechanisms. *Eur J Heart Fail.* 2014;16(3):281-8.
141. Hou Z-Q, Sun Z-X, Su C-Y, Tan H, Zhong X, Hu B, et al. Effect of levosimendan on estimated glomerular filtration rate in hospitalized patients with decompensated heart failure and renal dysfunction. *Cardiovasc Ther.* 2013;31(2):108-14.
142. Edner M, Benson L, Dahlstrom U, Lund LH. Association between renin-angiotensin system antagonist use and mortality in heart failure with severe renal insufficiency: a prospective propensity score-matched cohort study. *Eur Heart J.* 2015;36(34):2318-26.
143. Sharma P, Nagarajan V. Q: Can an ARB be given to patients who have had angioedema on an ACE inhibitor? *Cleve Clin J Med.* 2013;80(12):755-7.
144. Zachariah D, Kalra PA, Kalra PR. Optimal management of chronic heart failure in patients with chronic kidney disease. *J Ren Care.* 2009;35(1):2-10.
145. Anand IS, Deswal A, Kereiakes DJ, Purkayastha D, Zappe DH. Comparison of once-daily versus twice-daily dosing of valsartan in patients with chronic stable heart failure. *Vasc Health Risk Manag.* 2010;6:449-55.
146. Iglesias JI, DePalma L, Hom D, Antoniotti M, Ayoub S, Levine JS. Predictors of mortality in adult patients with congestive heart failure receiving nesiritide--retrospective analysis showing a potential adverse interaction between nesiritide and acute renal dysfunction. *Nephrol Dial Transplant.* 2008;23(1):144-53.
147. Ezekowitz JA, Hernandez AF, O'Connor CM, Starling RC, Proulx G, Weiss MH, et al. Assessment of dyspnea in acute decompensated heart failure: insights from ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) on the contributions of peak expiratory flow. *J Am Coll Cardiol.* 2012;59(16):1441-8.
148. Bernheim AM, Kittipovanonth M, Scott CG, McCully RB, Tsang TS, Pellikka PA. Relation of dyspnea in patients unable to perform exercise stress testing to outcome and myocardial ischemia. *Am J Cardiol.* 2009;104(2):265-9.
149. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2013.
150. Fisher KA, Stefan MS, Darling C, Lessard D, Goldberg RJ. Impact of COPD on the mortality and treatment of patients hospitalized with acute decompensated heart failure: the Worcester Heart Failure Study. *Chest.* 2015;147(3):637-45.
151. Johnson MJ, Oxberry SG. The management of dyspnoea in chronic heart failure. *Curr Opin Support Palliat Care.* 2010;4(2):63-8.
152. Zeng Q, Jiang S. Update in diagnosis and therapy of coexistent chronic obstructive pulmonary disease and chronic heart failure. *J Thorac Dis.* 2012;4(3):310-5.
153. Tallman TA, Peacock WF, Emerman CL, Lopatin M, Blicker JZ, Weber J, et al. Noninvasive ventilation outcomes in 2,430 acute decompensated heart failure patients: an ADHERE Registry Analysis. *Acad Emerg Med.* 2008;15(4):355-62.
154. Banerjee P, Tanner G, Williams L. Intravenous diuretic day-care treatment for patients with heart failure. *Clin Med.* 2012;12(2):133-6.
155. Cranston JM, Crockett A, Currow D. Oxygen therapy for dyspnoea in adults. *Cochrane Database Syst Rev.* 2008(3):CD004769.
156. Singer AJ, Emerman C, Char DM, Heywood JT, Kirk JD, Hollander JE, et al. Bronchodilator therapy in acute decompensated heart failure patients without a history of chronic obstructive pulmonary disease. *Ann Emerg Med.* 2008;51(1):25-34.
157. Bitter T, Westerheide N, Prinz C, Hossain MS, Vogt J, Langer C, et al. Cheyne-Stokes respiration and obstructive sleep apnoea are independent risk factors for malignant ventricular arrhythmias requiring appropriate cardioverter-defibrillator therapies in patients with congestive heart failure. *Eur Heart J.* 2011;32(1):61-74.

158. Bitter T, Faber L, Hering D, Langer C, Horstkotte D, Oldenburg O. Sleep-disordered breathing in heart failure with normal left ventricular ejection fraction. *Eur J Heart Fail.* 2009;11(6):602-8.
159. Javaheri S. CPAP should not be used for central sleep apnea in congestive heart failure patients. *J Clin Sleep Med.* 2006;2(4):399-402.
160. Javaheri S, Shukla R, Zeigler H, Wexler L. Central sleep apnea, right ventricular dysfunction, and low diastolic blood pressure are predictors of mortality in systolic heart failure. *J Am Coll Cardiol.* 2007;49(20):2028-34.
161. Oldenburg O, Lamp B, Faber L, Teschler H, Horstkotte D, Topfer V. Sleep-disordered breathing in patients with symptomatic heart failure: a contemporary study of prevalence in and characteristics of 700 patients. *Eur J Heart Fail.* 2007;9(3):251-7.
162. Schulz R, Blau A, Borgel J, Duchna HW, Fietze I, Koper I, et al. Sleep apnoea in heart failure. *Eur Respir J.* 2007;29(6):1201-5.
163. Bradley TD. The ups and downs of periodic breathing: implications for mortality in heart failure. *J Am Coll Cardiol.* 2003;41(12):2182-4.
164. Smith LA, Vennelle M, Gardner RS, McDonagh TA, Denvir MA, Douglas NJ, et al. Auto-titrating continuous positive airway pressure therapy in patients with chronic heart failure and obstructive sleep apnoea: a randomized placebo-controlled trial. *Eur Heart J.* 2007;28(10):1221-7.
165. Abraham WT, Trupp RJ, Phillips B, Bourge RC, Harding SM, Schofield P, et al. Effect of treatment with continuous positive airway pressure or oxygen on sleep-disordered breathing in patients with heart failure: results of the Sleep Events, Arrhythmias, and Respiratory Analysis in Chronic Heart Failure (SEARCH) study. *Congest Heart Fail.* 2008;14(4):197-201.
166. Bradley TD, Logan AG, Kimoff RJ, Series F, Morrison D, Ferguson K, et al. Continuous positive airway pressure for central sleep apnea and heart failure. *N Engl J Med.* 2005;353(19):2025-33.
167. Kaneko H, Yajima J, Oikawa Y, Tanaka S, Fukamachi D, Suzuki S, et al. Impact of aging on the clinical outcomes of Japanese patients with coronary artery disease after percutaneous coronary intervention. *Heart Vessels.* 2014;29(2):156-64.
168. Kauta SR, Keenan BT, Goldberg L, Schwab RJ. Diagnosis and treatment of sleep disordered breathing in hospitalized cardiac patients: a reduction in 30-day hospital readmission rates. *J Clin Sleep Med.* 2014;10(10):1051-9.
169. Abe H, Takahashi M, Yaegashi H, Eda S, Kitahara H, Tsunemoto H, et al. Valve repair improves central sleep apnea in heart failure patients with valvular heart diseases. *Circ J.* 2009;73(11):2148-53.
170. Brill A-K, Rösti R, Hefti JP, Bassetti C, Gugger M, Ott SR. Adaptive servo-ventilation as treatment of persistent central sleep apnea in post-acute ischemic stroke patients. *Sleep Med.* 2014;15(11):1309-13.
171. Carnevale C, Georges M, Rabec C, Tamisier R, Levy P, Pépin J-L. Effectiveness of Adaptive Servo Ventilation in the treatment of hypocapnic central sleep apnea of various etiologies. *Sleep Med.* 2011;12(10):952-8.
172. D'Elia E, Vanoli E, La Rovere MT, Fanfulla F, Maggioni A, Casali V, et al. Adaptive servo ventilation reduces central sleep apnea in chronic heart failure patients: beneficial effects on autonomic modulation of heart rate. *J Cardiovasc Med (Hagerstown).* 2013;14(4):296-300.
173. Kasai T, Kasagi S, Maeno K-I, Dohi T, Kawana F, Kato M, et al. Adaptive servo-ventilation in cardiac function and neurohormonal status in patients with heart failure and central sleep apnea nonresponsive to continuous positive airway pressure. *JACC Heart Fail.* 2013;1(1):58-63.
174. Kasai T, Narui K, Dohi T, Takaya H, Yanagisawa N, Dungan G, et al. First experience of using new adaptive servo-ventilation device for Cheyne-Stokes respiration with central sleep apnea among Japanese patients with congestive heart failure: report of 4 clinical cases. *Circ J.* 2006;70(9):1148-54.
175. Kasai T, Usui Y, Yoshioka T, Yanagisawa N, Takata Y, Narui K, et al. Effect of flow-triggered adaptive servo-ventilation compared with continuous positive airway pressure in patients with chronic heart failure with coexisting obstructive sleep apnea and Cheyne-Stokes respiration. *Circ Heart Fail.* 2010;3(1):140-8.
176. Randerath WJ, Nothofer G, Priegnitz C, Anduleit N, Tremml M, Kehl V, et al. Long-term auto-servoventilation or constant positive pressure in heart failure and coexisting central with obstructive sleep apnea. *Chest.* 2012;142(2):440-7.
177. Takama N, Kurabayashi M. Safety and efficacy of adaptive servo-ventilation in patients with severe systolic heart failure. *J Cardiol.* 2014;63(4):302-7.
178. Koyama T, Watanabe H, Kobukai Y, Makabe S, Munehisa Y, Iino K, et al. Beneficial effects of adaptive servo ventilation in patients with chronic heart failure. *Circ J.* 2010;74(10):2118-24.
179. Broström A, Johansson P. Sleep disturbances in patients with chronic heart failure and their holistic consequences-what different care actions can be implemented? *Eur J Cardiovasc Nurs.* 2005;4(3):183-97.

180. Czarnecka D, Kusiak A, Wiliński J, Styczkiewicz K, Wojciechowska W, Baciór B, et al. Effects of cardiac resynchronization therapy on sleep apnea, quality of sleep and daytime sleepiness in patients with chronic heart failure. *Prz Lek.* 2010;67(12):1249-52.
181. Yamamoto U, Mohri M, Shimada K, Origuchi H, Miyata K, Ito K, et al. Six-month aerobic exercise training ameliorates central sleep apnea in patients with chronic heart failure. *J Card Fail.* 2007;13(10):825-9.
182. Martin CR, Woehrie H, Wegscheider K, et al.. Rationale and design of the SERVE-HF study: treatment of sleep-disordered breathing with predominant central sleep apnoea with adaptive servo-ventilation in patients with chronic heart failure. *Eur J Heart Fail.* 2013;15(8):937-43.
183. Chaudhari D, Gangadharan V, Forrest T. Heart failure presenting as myxedema coma: case report and review article. *Tenn Med.* 2013;106(5):39-40.
184. van Deursen VM, Urso R, Laroche C, Damman K, Dahlstrom U, Tavazzi L, et al. Co-morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey. *Eur J Heart Fail.* 2014;16(1):103-11.
185. Marzouka G, Cortazar F, Alvarez JA, Dias A, Hebert K. Racial and sex differences in prevalence of hypothyroidism in patients with cardiomyopathies enrolled into a heart failure disease management program. *Congest Heart Fail.* 2011;17(3):133-9.
186. Chen S, Shauer A, Zwas DR, Lotan C, Keren A, Gotsman I. The effect of thyroid function on clinical outcome in patients with heart failure. *Eur J Heart Fail.* 2014;16(2):217-26.
187. Metso S, Auvinen A, Salmi J, Huhtala H, Jaatinen P. Increased long-term cardiovascular morbidity among patients treated with radioactive iodine for hyperthyroidism. *Clin Endocrinol.* 2008;68(3):450-7.
188. Ryödi E, Salmi J, Jaatinen P, Huhtala H, Saaristo R, Välimäki M, et al. Cardiovascular morbidity and mortality in surgically treated hyperthyroidism - a nation-wide cohort study with a long-term follow-up. *Clin Endocrinol.* 2014;80(5):743-50.
189. Gencer B, Collet T-H, Virgini V, Bauer DC, Gussekloo J, Cappola AR, et al. Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts. *Circulation.* 2012;126(9):1040-9.
190. Gerdes AM, Iervasi G. Thyroid replacement therapy and heart failure. *Circulation.* 2010;122(4):385-93.
191. Ventrella S, Kolin I. Beta-adrenergic receptor blocking drugs in the management of hyperthyroidism. *Endocrinologist.* 1994;4:391.
192. Danzi S, Klein I. Thyroid hormone and blood pressure regulation. *Curr Hypertens Rep.* 2003;5(6):513-20.
193. Sharma AK, Vegh E, Orencole M, Miller A, Blendea D, Moore S, et al. Association of hypothyroidism with adverse events in patients with heart failure receiving cardiac resynchronization therapy. *Am J Cardiol.* 2015;115(9):1249-53.
194. Klein I, Danzi S. Thyroid disease and the heart. *Circulation.* 2007;116(15):1725-35.
195. Brandt F, Thvilum M, Almind D, Christensen K, Green A, Hegedus L, Heiberg Brix T. Morbidity before and after the Diagnosis of Hyperthyroidism: A Nationwide Register-Based Study. *PLoS One.* 2013;8(6):e66711.